Nigel Rogers - Executive Chairman
Nigel qualified as a Chartered Accountant in 1983 spending eight years with PwC before moving into industry. He managed the flotation of Stadium Group plc (“Stadium”) as Group Finance Director, before progressing to Group Chief Executive Officer in 2001. He joined 600 Group plc as Group Chief Executive Officer in 2012 and led the turnaround of the AIM-quoted global machine tool business (Colchester-Harrison), increasing strategic focus on the growth of its laser marking business (Electrox) until April 2015. Nigel has been Non-Executive Deputy Chairman of Transense Technologies plc, the AIM-quoted provider of sensor systems, since July 2015. Nigel was appointed Executive Chairman of Surgical Innovations Group plc in October 2015.
Melanie Ross - Chief Operating Officer and Group Finance Director
Melanie qualified as a Chartered Management Accountant in 2006 training as a graduate with Corus before moving on to gain commercial exposure at the European Headquarters of Fellowes Inc. Melanie then moved on to Eaton Cooper Lighting & Safety Ltd, progressing through various roles to Business Partner – Finance before changing focus and moving to AESSEAL plc as Business Development Manager. It was her work here that led to a secondment over to Surgical Innovations Group plc as a consultant, working with the incumbent management on a full strategic review. Melanie transitioned over from AESSEAL in July 2015, and was appointed Finance Director (and Company Secretary) of the Group in the August, as well as General Manager of the main trading subsidiary. In October 2015 Melanie was appointed Managing Director, and subsequently Chief Operating Officer of the Group in December 2016.
Adam Power – Group Development Director
Adam has over 25 years’ experience managing companies selling Medical Devices. He has been responsible for the introduction into the UK of some of the most innovative solutions for surgical problems in the past two decades. Adam and his team introduced the Gastric Band for obesity, the Intuitive daVinci robot and Endovascular Aneurysm repair, all of which have become adopted by the NHS. Following the successful sale of his company, Mantis Surgical, Adam co-founded Elemental Healthcare with David Marsh in 2006. Elemental Healthcare has continued this tradition of innovation and growth, with the launch of a number of new technologies such as the Endobarrier endoluminal device for the surgical control of T2 Diabetes and the continued growth of Elemental’s key suppliers.
David Marsh – Group Commercial Director
David has over 25 years’ experience within the medical industry, 20 of which have been in senior management positions. David joined Auto Suture (Medtronic ) in 1991 before being appointed Sales Director then General Manager of SkyMed Ltd. Following the acquisition of SkyMed by Gyrus David was appointed Managing Director of the Direct Operations in U.K. Benelux and Germany, before assuming the position of Vice President of Sales and Marketing for Europe. As part of the Gyrus Senior Management team David was involved in the many acquisitions made by the Company and led the European integration of the enlarged business. During his career David has been responsible for the introduction of a number of key technologies across a broad spectrum of specialities. In 2006 David was Co-Founder of Elemental Healthcare Ltd.
Professor Mike McMahon - Non Executive Clinical Director
Mike, a founder Director of Surgical Innovations Ltd, became Non-executive Clinical Director in October 2007. He is an
Emeritus Prof of Surgery at the University of Leeds, and practices as a Consultant Surgeon at the Nuffield Hospital, Leeds. He has carried out research and development of laparoscopic surgery and has demonstrated operative techniques in many countries. He is past President of the Association of Laparoscopic Surgeons of Great Britain and Ireland and was also Tutor in MIS at the Royal College of Surgeons and Director of the Leeds Institute for Minimally Invasive Therapy.
Mike’s past roles include President of the Pancreatic Society of Great Britain and Ireland and Chairman of the Education
Committee of the European Association of Endoscopic Surgery. He is a Non-executive Director of Cipher Surgical Limited.
Paul Hardy - Non Executive Director
After qualifying as a Chartered Accountant in 1984, Paul moved into the engineering industry which culminated in leading the private equity-backed management buyout of BI Engineering Limited, a £60m turnover group of aerospace and med-tech businesses in the UK and US. The medical division was subsequently sold to a US venture capital buyer for in excess of US$200m. Since 2003, he has owned and led Hardy Transaction Management Limited, a boutique provider of merger and acquisition lead advisory services.
Alistair Taylor - Non Executive Director
Alistair is a vastly experienced director in life science companies with exposure to both pharmaceutical and med-tech sectors. After forging a successful career with Beecham Group Limited and Pfizer Inc., he has gone on to lead a number of public and private businesses in the medical field in the UK and internationally, initially as CEO of Biocompatibles plc, and later as Chairman of Lombard Medical Technology plc, and Phytopharm plc amongst others.
Charmaine Day - Company Secretary
Charmaine qualified as a Chartered Certified Accountant in 2012. Beginning her career in finance for Eville & Jones Ltd whilst qualifying as an Accounting Technician. Charmaine then progressed in various roles and moved on to Ellis Fairbank PLC as a Management Accountant and has been working for Surgical Innovations as a Financial Controller since 2012, taking on the role of Company Secretary in 2017.